Governance
Investors

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

 

Oct 02 2023
, ,

02 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

More details
Sep 29 2023
, ,

Philogen kindly invites you to attend a virtual briefing for analysts on 2 October 2023 to discuss Company’s Half Year 2023 Results

We are delighted to invite you to our virtual briefing on 2 October 2023 to discuss the Company’s Half Year 2023 Results.Prof. Dr. Dario Neri, Chief Executive Officer,...
Sep 29 2023
, ,

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2023 (Price sensitive) – Courtesy English Translation

more details
Sep 29 2023
, ,

Philogen to attend the Festival of Biologics 2023 congress in Basel on October 10-12, 2023

Dr. Samuele Cazzamalli (Head of Chemistry) will give a talk entitled "Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment”...
Sep 29 2023
, ,

Philogen to attend the World ADC 2023 congress in San Diego on October 16-19, 2023

Dr. Samuele Cazzamalli (Head of Chemistry) will give a virtual talk entitled "Pan-tumoral Small Molecule-Drug Conjugates Targeting Fibroblast Activation Protein in...
Sep 29 2023
, ,

Philogen to attend the ESMO congress in Madrid on October 20-24, 2023

Prof. Dr. Nicolas Mach, on behalf of Philogen, is presenting a poster about the Phase I DODEKA study on October 23rd, entitled “Phase I dose-escalation trial with...
Sep 29 2023
, ,

Philogen to attend the 12th annual Cell Culture & Bioprocessing Congress in London on November 07-08, 2023.

Dr. Mattia Matasci is giving a presentation entitled “Philogen’s Platform for the Development of Immunocytokines”. Follow the link for more details
Sep 29 2023
, ,

Philogen to attend the PEGS Europe 2023 congress in Lisbon on November 14-16, 2023

Dr. Roberto De Luca will give a talk entitled "Tripokin: Best-in-Class potential for tumor targeted Interleukin-2 (IL2) potentiated by Tumor Necrosis Factor (TNF)”...
Sep 29 2023
, ,

Philogen to attend the EFMC International Symposium on Chemical Biology 2023 congress in Basel on November 16-18, 2023

Dr. Samuele Cazzamalli (Head of Chemistry) will give a talk entitled "Small Molecule Therapeutics Targeting Fibroblast Activation Protein in the Tumor Microenvironment”...
Sep 28 2023
, ,

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2023 (Price sensitive)

more details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions